These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 2260171

  • 1. Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime.
    Netto EM, Marsden PD, Llanos-Cuentas EA, Costa JM, Cuba CC, Barreto AC, Badaró R, Johnson WD, Jones TC.
    Trans R Soc Trop Med Hyg; 1990; 84(3):367-70. PubMed ID: 2260171
    [Abstract] [Full Text] [Related]

  • 2. Personal experience with diagnostic and therapeutic aspects of human Leishmania (Viannia) braziliensis in Três Braços.
    Marsden PD.
    Mem Inst Oswaldo Cruz; 1994; 89(3):485-7. PubMed ID: 7476237
    [Abstract] [Full Text] [Related]

  • 3. [A comparative study between sodium stibogluconate BP 88R and meglumine antimoniate in the treatment of cutaneous leishmaniasis. I. The efficacy and safety].
    Saldanha AC, Romero GA, Merchan-Hamann E, Magalhães AV, Macedo Vde O.
    Rev Soc Bras Med Trop; 1999; 32(4):383-7. PubMed ID: 10495667
    [Abstract] [Full Text] [Related]

  • 4. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.
    Pimentel MI, Baptista C, Rubin EF, Vasconcellos Ede C, Lyra MR, Salgueiro Mde M, Saheki MN, Rosalino CM, Madeira Mde F, Silva AF, Confort EM, Schubach Ade O.
    Rev Soc Bras Med Trop; 2011; 44(2):254-6. PubMed ID: 21552747
    [Abstract] [Full Text] [Related]

  • 5. Low dose glucantime therapy in Leishmania viannia braziliensis (Lvb) infections.
    Costa JM, Marsden PD.
    Rev Soc Bras Med Trop; 1988; 21(2):85-6. PubMed ID: 3249826
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.
    Romero GA, Guerra MV, Paes MG, Macêdo VO.
    Am J Trop Med Hyg; 2001 Nov; 65(5):456-65. PubMed ID: 11716098
    [Abstract] [Full Text] [Related]

  • 7. Responses of Leishmania (Viannia) braziliensis cutaneous infection to N-methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model.
    Teva A, Porrozzi R, Oliveira-Neto MP, Grimaldi GJ.
    J Parasitol; 2005 Aug; 91(4):976-8. PubMed ID: 17089782
    [Abstract] [Full Text] [Related]

  • 8. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
    Azeredo-Coutinho RB, Mendonça SC, Callahan H, Portal AC, Max G.
    J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
    [Abstract] [Full Text] [Related]

  • 9. [Leishmaniasis caused by Leishmania viannia braziliensis (Lvb). A case of atypical course].
    Costa JM, Vale KC, França F, Lago EL, Magalhães AV, Marsden PD, Sampaio RN.
    Rev Soc Bras Med Trop; 1988 Jun; 21(2):71-3. PubMed ID: 2854901
    [No Abstract] [Full Text] [Related]

  • 10. Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala.
    Navin TR, Arana BA, Arana FE, de Mérida AM, Castillo AL, Pozuelos JL.
    Am J Trop Med Hyg; 1990 Jan; 42(1):43-50. PubMed ID: 2405727
    [Abstract] [Full Text] [Related]

  • 11. Genotypic profiles of Leishmania (Viannia) braziliensis strains from cutaneous leishmaniasis patients and their relationship with the response to meglumine antimoniate treatment: a pilot study.
    Gagini T, de Oliveira Schubach A, de Fatima Madeira M, Maria Valete-Rosalino C, Fernandes Pimentel MI, da Silva Pacheco R.
    Parasite; 2017 Jan; 24():34. PubMed ID: 28959938
    [Abstract] [Full Text] [Related]

  • 12. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years).
    Oliveira-Neto MP, Schubach A, Mattos M, Goncalves-Costa SC, Pirmez C.
    Am J Trop Med Hyg; 1997 Dec; 57(6):651-5. PubMed ID: 9430521
    [Abstract] [Full Text] [Related]

  • 13. Retention of antimony in hair during leishmaniasis treatment.
    Dorea JG, Merchan-Hamann E, Ryan DE, Holzbecher J.
    Clin Chim Acta; 1989 Feb 22; 179(3):341-5. PubMed ID: 2714007
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Intralesional glucantime in Leishmania braziliensis braziliensis infections.
    Barrios LA, Costa JM, Netto EM, Vexenat CO, Cuba CC, Marsden PD.
    Trans R Soc Trop Med Hyg; 1986 Feb 22; 80(1):173-4. PubMed ID: 3726989
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cutaneous leishmaniasis in Bolivia. A study of 185 human cases from Alto Beni (La Paz Department). Isolation and isoenzyme characterization of 26 strains of Leishmania braziliensis braziliensis [corrected].
    Desjeux P, Mollinedo S, Le Pont F, Paredes A, Ugarte G.
    Trans R Soc Trop Med Hyg; 1987 Feb 22; 81(5):742-6. PubMed ID: 3449990
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Disseminated cutaneous leishmaniasis caused by Leishmania braziliensis in Southern Brazil.
    Membrive NA, Kazuma FJ, Silveira TGV, Teixeira JJV, Reinhold-Castro KR, Teodoro U.
    Rev Inst Med Trop Sao Paulo; 2017 Jun 01; 59():e37. PubMed ID: 28591265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.